Everton Rowe

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou et al. · The Lancet Diabetes & Endocrinology · 2017 · 414 citations

Sustain 4, Diabetes Management, Insulin-naive Patients +8

Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension

F. Gilbert McMahon, Ken Fujioka, Bramah N. Singh et al. · Archives of Internal Medicine · 2000 · 247 citations

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Ken Fujioka, T. B. Seaton, Everton Rowe et al. · Diabetes Obesity and Metabolism · 2000 · 244 citations

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

Lene Jensen, Hans Helleberg, Ad F. Roffel et al. · European Journal of Pharmaceutical Sciences · 2017 · 161 citations · Full text

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

F. Gilbert McMahon, Samuel Weinstein, Everton Rowe et al. · Journal of Human Hypertension · 2002 · 110 citations

Obesity, Metabolic Syndrome, Hypertension +12